Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleukin (interleukin 2) and IFN-α2a therapy in metastatic renal cell carcinoma patients

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4986-4992

  Schwaab, Thomas ^a   Schwarzer, Adrian ^a   Wolf, Benita ^a   Crocenzi, Todd S ^c   Seigne, John D ^a   Crosby, Nancy A ^a   Cole, Bernard F ^a   Fisher, Jan L ^a   Uhlenhake, Jill C ^a   Mellinger, Diane ^a   Foster, Cathy ^a   Szczepiorkowski, Zbigniew M ^a   Webber, Susan M ^a   Schned, Alan R ^a   Harris, Robert D ^a   Barth Jr , Richard J ^a   Heaney, John A ^a   Noelle, Randolph J ^a,b   Ernstoff, Marc S ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Earle A Chiles Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONFUSION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DENDRITIC CELL; DERMATITIS; DIARRHEA; EDEMA; EX VIVO STUDY; FATIGUE; FEMALE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LUNG EMBOLISM; LUNG TOXICITY; LYMPHOCYTOPENIA; MALE; MENTAL HEALTH; METABOLISM; METASTASIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHRITIS; OLIGURIA; PAROTITIS; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SINUS TACHYCARDIA; SOMNOLENCE; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL10; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2A; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 68049140780     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3240     Document Type: Article

References (49)

1. Schwaab T, Atzpodien J. Renal Cell Carcinoma. In: Kirkwood J, editor. Strategies in Immunoadjuvant Therapies. Dunitz Publishers, 2000.
2. Motzer RJ, Mazumdar M, Bacik , et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:1928-1935 (Pubitemid 30261931)
3. Ernstoff MS, Nair S, Bahnson RR, et al. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon Υ and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 1990;8:1637-1649 (Pubitemid 20334318)
4. Figdor CG, deVries JM, Lesterhuis WJ, Melief CJM. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480
5. McIntyre CA, Chapman K, Reeder S, et al. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin- 2: analysis of cytokine levels in sera and culture supernatants. Eur J Cancer 1992; 26:58-63.
6. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-670 (Pubitemid 23105674)
7. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:1188-1194 (Pubitemid 41079830)
8. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434 (Pubitemid 36910021)
9. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
10. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388-92S.
11. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918 (Pubitemid 41103603)
12. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998;338:1272-1278
13. Goedegebuure PS, Douville LM, Li H, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995;13: 1939-1949
14. Finke JH, Rayman P, Edinger M, et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1992;11:1-11.
15. Jantzer P, Schendel DJ. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 1998;58:3078-3086 (Pubitemid 28335090)
16. Wiethe C, Dittmar K, Doan T, et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumorassociated antigen. J Immunol2003;170:2912-2922
17. Banchereau J, Steinman RM. Dendritic cells and control of immunity. Nature 1998;392: 245-252
18. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296
19. Gabrilovitch DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-490 (Pubitemid 27158075)
20. Troy AJ, Summers KL, Davidson PJT, Atkinson CH, Hart DNJ. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998;4:585-593
21. Schwaab T, Schned AR, Heaney JA, et al. In vivo description of dendritic cells in human renal cell carcinoma. J Urol 1999;162:567-573
22. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998;95:9482-9494
23. Lou Y, Wang G, Lizée G, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 2004;64: 6783-6790 (Pubitemid 39297942)
24. Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003;26:85-93.
25. Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001;61:641-646 (Pubitemid 32128627)
26. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003;21: 3826-3835 (Pubitemid 46606238)
27. Yang JCY. Interleukin-2: Clinical Applications: Renal Cell Carcinoma. In: Rosenberg SA, editor. Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 73-82.
28. Kaser A, Nagata S, Tilg H. Interferon α augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 1999;11:736-743 (Pubitemid 29460471)
29. Radvanyi LG, Banerjee A, Weir M, Messner H. Low levels of interferon-α induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 1999;50: 499-509.
30. Anderson PO, Sundstedt A, Yazici Z, et al. IL-2 overcomes the unresponsiveness but fails to reverse the regulatory function of antigen-induced T regulatory cells. J Immunol 2005;174:310-319 (Pubitemid 40007418)
31. Knoefel B, Nuske K, Steiner T, et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-β 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 1997;17:95-102. (Pubitemid 27100287)
32. Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down regulation of tumor immunosurveillance. J Exp Med 2005;202: 1627-1633 (Pubitemid 41815868)
33. Ernstoff MS, Crocenzi TS, Seigne JD, et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res 2007;13:733-40s.
34. Spiotto MT, Fu Y, Schreiber H. Tumor immunity meets autoimmunity: levels and dendritic. Curr Opin Immunol 2003;15:725-30.
35. Tsunenori K, Hayakazu N. Cancer Sci 2006;97: 780-786
36. Givan AL, Fisher JL, Waugh MG, Bercovici N, Wallace PK. Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. Methods Mol Biol 2004;263:109-124
37. Crocenzi TS, Tretter CPG, Schwaab T, et al. Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients. Clin Immunol 2005;117:6-11. (Pubitemid 41725463)
38. Oberg HH, Wesch D, Lenke J, et al. An optimized method for the functional analysis of human regulatory T cells. Scand J Immunol 2006; 64:353-360 (Pubitemid 44215126)
39. Kim JH, Lee Y, Bae YS, et al. Phase I/II study of immunotherapy using autologous tumor lysatepulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007;125: 257-267 (Pubitemid 350116707)
40. Suppiah R. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during Sunitinib treatment: correlation with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. Proc ASCO 2006;.
41. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997;61: 246-257
42. Panelli MC, White R, Foster M, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004;2: 17-31. (Pubitemid 39130355)
43. Uemura H, Fujimoto K, Tanaka M, et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine- refractory metastatic renal cell carcinoma. Clin Cancer Res 2006;12:1768-1775
44. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9 peptide-pulsed mature dendritic cells. J Immunother 2007;30:116-122 (Pubitemid 46052210)
45. Satzger I, Meier A, Schenck F, et al. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon α. Int J Cancer 2007;121:2562-2567 (Pubitemid 350022429)
46. Amato RJ. Vaccine therapy for renal cell carcinoma. Rev Urol 2003;5:65-71.
47. Ernstoff MS. Self-recognition and tumor response to immunotherapy. J Clin Oncol 2005; 23:5875-5877
48. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718 (Pubitemid 43247141)
49. Schwaab T, Heaney JA, Schned AR, et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon γ and human recombinant interferon α 2b therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 2000;163:1322-1327 (Pubitemid 30169433)